{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T10:12:51Z","timestamp":1787911971302,"version":"build-2784847793"},"reference-count":19,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"8","license":[{"start":{"date-parts":[[2023,4,27]],"date-time":"2023-04-27T00:00:00Z","timestamp":1682553600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,8]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>This study investigated the immunogenicity and safety of a fully liquid, hexavalent, diphtheria (D)-tetanus (T)-whole-cell pertussis (wP)-inactivated poliovirus (IPV)-hepatitis B (HB)-<jats:italic toggle=\"yes\">Haemophilus influenzae<\/jats:italic> b (PRP-T) vaccine compared to licensed DTwP-HB-PRP~T, IPV, and bivalent oral poliovirus (bOPV) vaccines following co-administration with other pediatric vaccines [pneumococcal conjugate vaccine (PCV13) and rotavirus vaccine].<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>Phase III, randomized, open-label study in Thailand. Healthy infants received DTwP-IPV-HB-PRP~T at 2, 4 and 6 months of age (N = 228), or DTwP-HB-PRP~T and bOPV (2, 4 and 6 months of age) and IPV (4 months of age) (N = 231). All participants received PCV13 (2, 4 and 6 months of age) and rotavirus vaccine (2 and 4 months of age). Immunogenicity for all antigens was assessed using validated assays, and noninferiority post-third dose was evaluated for anti-D, anti-T, anti-pertussis [anti-pertussis toxin (anti-PT) and anti-fimbriae 2\/3 (anti-FIM)], anti-polio 1, 2, 3, anti-HB, and anti-PRP~T. Safety was assessed using parental reports.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>Noninferiority was demonstrated for each antigen, and overall noninferiority of DTwP-IPV-HB-PRP~T versus DTwP-HB-PRP~T+bOPV+IPV was concluded. Similarity in each group was observed for the GMC ratio for antirotavirus antibodies (20.9 and 17.3, respectively) and anti-PCV13 antibodies (range: 8.46\u201332.6 and 7.53\u201333.1, respectively). Two serious adverse events were related to DTwP-IPV-HB-PRP~T (febrile convulsion and acute febrile illness) and 1 was related to DTwP-HB-PRP~T+bOPV+IPV (febrile seizure), but overall there were no safety concerns with similar rates of participants experiencing solicited (99.1% and 98.3%) and unsolicited (19.3% and 19.5%) adverse events in each group.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>This study confirmed the suitability of DTwP-IPV-HB-PRP~T primary series vaccination in combination with rotavirus and PCV13 vaccines.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/inf.0000000000003975","type":"journal-article","created":{"date-parts":[[2023,5,31]],"date-time":"2023-05-31T20:01:29Z","timestamp":1685563289000},"page":"711-718","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":3,"title":["Immunogenicity and Safety of a Hexavalent DTwP-IPV-HB-PRP~T Vaccine Versus Separate DTwP-HB-PRP~T, bOPV, and IPV Vaccines Administered at 2, 4, 6 Months of Age Concomitantly With Rotavirus and Pneumococcal Conjugate Vaccines in Healthy Infants in Thailand"],"prefix":"10.1097","volume":"42","author":[{"given":"Leilani","family":"Sanchez","sequence":"first","affiliation":[{"name":"Sanofi, Taguig City, Philippines"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Supattra","family":"Rungmaitree","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pope","family":"Kosalaraksa","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Faculty of Medicine, Khon Kaen University, Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Watsamon","family":"Jantarabenjakul","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, King Chulalongkorn Memorial Hospital, Bangkok, Thailand"},{"name":"Department of Pediatrics, Center of Excellence for Pediatric Infectious Diseases and Vaccines, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Leclercq","sequence":"additional","affiliation":[{"name":"AIXIAL, Boulogne-Billancourt, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuvadee","family":"Yaiprayoon","sequence":"additional","affiliation":[{"name":"Sanofi, Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Venkata Jayanth","family":"Midde","sequence":"additional","affiliation":[{"name":"Sanofi Healthcare India Private Limited, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kucku","family":"Varghese","sequence":"additional","affiliation":[{"name":"Sanofi, Swiftwater, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Somnath","family":"Mangarule","sequence":"additional","affiliation":[{"name":"Sanofi, Marcy l\u2019Etoile, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando","family":"Noriega","sequence":"additional","affiliation":[{"name":"Sanofi, Swiftwater, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2023,4,27]]},"reference":[{"key":"R2-20250614","doi-asserted-by":"crossref","first-page":"5485","DOI":"10.1016\/j.vaccine.2017.06.063","article-title":"New perspectives for hexavalent vaccines.","volume":"36","author":"Obando-Pacheco","year":"2018","journal-title":"Vaccine"},{"key":"R3-20250614","doi-asserted-by":"crossref","first-page":"100137","DOI":"10.1016\/j.jvacx.2021.100137","article-title":"Safety and immunogenicity of a hexavalent DTwP-IPV-HB-PRP~T vaccine versus separate DTwP-HB-PRP~T and IPV vaccines in healthy infants in India.","volume":"10","author":"Mangarule","year":"2022","journal-title":"Vaccine X"},{"key":"R4-20250614","doi-asserted-by":"crossref","first-page":"100190","DOI":"10.1016\/j.jvacx.2022.100190","article-title":"Antibody persistence following administration of a hexavalent DTwP-IPV-HB-PRP~T vaccine versus separate DTwP-HB-PRP~T and IPV vaccines at 12-24 months of age and safety and immunogenicity of a booster dose of DTwP-IPV-HB-PRP~T in healthy infants in India.","volume":"11","author":"Mangarule","year":"2022","journal-title":"Vaccine X"},{"key":"R5-20250614","doi-asserted-by":"crossref","first-page":"100216","DOI":"10.1016\/j.jvacx.2022.100216","article-title":"Lot-to-lot consistency of a hexavalent DTwP-IPV-HB-PRP~T vaccine and non-inferiority to separate DTwP-HB-PRP~T and IPV antigen-matching vaccines at 6-8, 10-12, and 14-16 weeks of age co-administered with oral rotavirus vaccine in healthy infants in India: a multi-center, randomized, controlled study.","volume":"12","author":"Mangarule","year":"2022","journal-title":"Vaccine X"},{"key":"R6-20250614","doi-asserted-by":"crossref","first-page":"5600","DOI":"10.1016\/j.vaccine.2018.07.048","article-title":"Development and application of a multiplex assay for the simultaneous measurement of antibody responses elicited by common childhood vaccines.","volume":"36","author":"Itell","year":"2018","journal-title":"Vaccine"},{"key":"R7-20250614","doi-asserted-by":"crossref","first-page":"2539","DOI":"10.1007\/s40121-021-00530-7","article-title":"A new electrochemiluminescence-based multiplex assay for the assessment of human antibody responses to Bordetella pertussis vaccines.","volume":"10","author":"Varghese","year":"2021","journal-title":"Infect Dis Ther"},{"key":"R8-20250614","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1002\/(SICI)1097-0258(19980430)17:8<857::AID-SIM777>3.0.CO;2-E","article-title":"Two-sided confidence intervals for the single proportion: comparison of seven methods.","volume":"17","author":"Newcombe","year":"1998","journal-title":"Stat Med"},{"issue":"13 Suppl","key":"R9-20250614","first-page":"203","article-title":"Agglutinogens and fimbriae of Bordetella pertussis.","author":"Ashworth","year":"1988","journal-title":"Tokai J Exp Clin Med"},{"key":"R10-20250614","doi-asserted-by":"crossref","first-page":"ftv073","DOI":"10.1093\/femspd\/ftv073","article-title":"Contribution of pertussis toxin to the pathogenesis of pertussis disease.","volume":"73","author":"Carbonetti","year":"2015","journal-title":"Pathog Dis"},{"key":"R11-20250614","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1093\/infdis\/jiy022","article-title":"Maternal vaccination with a monocomponent pertussis toxoid vaccine is sufficient to protect infants in a baboon model of whooping cough.","volume":"217","author":"Kapil","year":"2018","journal-title":"J Infect Dis"},{"key":"R12-20250614","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1016\/S0022-3476(43)80220-1","article-title":"An agglutinative reaction for Haemophilus pertussis: II. Its relation to clinical immunity.","volume":"22","author":"Miller","year":"1943","journal-title":"J Pediatr"},{"key":"R13-20250614","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0022-3476(47)80280-X","article-title":"Studies on pertussis immunization.","volume":"30","author":"Sako","year":"1947","journal-title":"J Pediatr"},{"key":"R14-20250614","doi-asserted-by":"crossref","first-page":"e249","DOI":"10.1016\/j.ijid.2010.12.004","article-title":"Immunogenicity and safety study of a new DTaP-IPV-Hep B-PRP-T combined vaccine compared to a licensed DTaP-IPV-Hep B\/\/PRP-T comparator, both concomitantly administered with a 7-valent pneumococcal conjugate vaccine at 2, 4, and 6 months of age in Thai infants.","volume":"15","author":"Kosalaraksa","year":"2011","journal-title":"Int J Infect Dis"},{"key":"R15-20250614","doi-asserted-by":"crossref","first-page":"e272","DOI":"10.1097\/INF.0000000000001682","article-title":"A randomized, controlled study of a fully liquid DTaP-IPV-HB-PRP-T hexavalent vaccine for primary and booster vaccinations of healthy infants and toddlers in Latin America.","volume":"36","author":"L\u00f3pez","year":"2017","journal-title":"Pediatr Infect Dis J"},{"key":"R16-20250614","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1097\/INF.0000000000002231","article-title":"Evaluation of a hexavalent-pentavalent-hexavalent infant primary vaccination series Followed by a pentavalent booster vaccine in healthy infants and toddlers.","volume":"38","author":"Martinon-Torres","year":"2019","journal-title":"Pediatr Infect Dis J"},{"key":"R17-20250614","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1097\/INF.0000000000002109","article-title":"Immunogenicity and safety of primary and booster vaccinations of a fully liquid DTaP-IPV-HB-PRP-T hexavalent vaccine in healthy infants and toddlers in Germany and the Czech Republic.","volume":"37","author":"Prymula","year":"2018","journal-title":"Pediatr Infect Dis J"},{"key":"R18-20250614","doi-asserted-by":"crossref","first-page":"3653","DOI":"10.1016\/S0264-410X(03)00389-X","article-title":"The safety, reactogenicity and immunogenicity of a 7-valent pneumococcal conjugate vaccine (7VPnC) concurrently administered with a combination DTaP-IPV-Hib vaccine.","volume":"21","author":"Schmitt","year":"2003","journal-title":"Vaccine"},{"key":"R20-20250614","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1542\/peds.68.5.650","article-title":"Nature and rates of adverse reactions associated with DTP and DT immunizations in infants and children.","volume":"68","author":"Cody","year":"1981","journal-title":"Pediatrics"},{"key":"R21-20250614","first-page":"433","article-title":"Pertussis vaccines: WHO position paper.","volume":"90","year":"2015","journal-title":"Wkly Epidemiol Rec"}],"container-title":["Pediatric Infectious Disease Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/INF.0000000000003975","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,15]],"date-time":"2025-06-15T00:05:12Z","timestamp":1749945912000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/INF.0000000000003975"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,27]]},"references-count":19,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1097\/inf.0000000000003975","relation":{},"ISSN":["0891-3668"],"issn-type":[{"value":"0891-3668","type":"print"}],"subject":[],"published":{"date-parts":[[2023,4,27]]}}}